性激素在前列腺增生中的作用
|
摘要
随着男性老龄化进程的加剧,体内性激素水平也发生相应的变化,与性激素相关疾病的发病率明显升高,其中以下尿路症状(LUTS)为主要临床表现的前列腺增生(BPH)患者日益增加,性激素与前列腺增生之间存在着紧密的联系。二者之间的相互关系已经成为各国学者研究的热点,本文就性激素在前列腺增生的发展进程中的作用做一综述。
As the process of male aging intensifies, the sexual hormone level in the body also changes accordingly, and the incidence of sexual hormone-related diseases increases significantly as the process of male aging intensifies. The following urinary tract symptoms(LUTS) are the main clinical manifestations of increased prostate hyperplasia(BPH) patients, sexual hormones and prostate hyperplasia are closely linked. The interrelationship between the two has become a hot topic of scholars in various countries. This article reviews the role of sex hormones in the development of prostate hyperplasia
As the process of male aging intensifies, the sexual hormone level in the body also changes accordingly, and the incidence of sexual hormone-related diseases increases significantly as the process of male aging intensifies. The following urinary tract symptoms(LUTS) are the main clinical manifestations of increased prostate hyperplasia(BPH) patients, sexual hormones and prostate hyperplasia are closely linked. The interrelationship between the two has become a hot topic of scholars in various countries. This article reviews the role of sex hormones in the development of prostate hyperplasia
引文
[1]Bassil N. Late-onset hypogonadism[J]. Medical Clinics of North America,2011, 95(3):507-523.
[2]Asiedu B, Anang Y, Nyarko A, et al. The role of sex steroid hormones in benign prostatic hyperplasia[J]. Aging Male, 2017, 20(1):17-22.
[3]Rogol A D. Androgens and puberty[J]. Molecular&Cellular Endocrinology,2002, 198(1):25-29.
[4]Gao W, Bohl C E, Dalton J T. Chemistry and structural biology of androgen receptor[J]. Chemical Reviews, 2005, 105(9):3352-70.
[5]Lamberts S W, Vandenbeld A W, Vanderlely A J. The endocrinology of aging[J]. Science,1997,278(5337):419.
[6]Kaplan S A, O'Neill E, Lowe R, et al. Prevalence of low testosterone in aging men with benign prostatic hyperplasia:data from the Proscar Long-term Efficacy and Safety Study(PLESS)[J]. Aging Male, 2013, 16(2):48-51.
[7]Kelsey T W, Li L Q, Mitchell R T, et al. A Validated Age-Related Normative Model for Male Total Testosterone Shows Increasing Variance but No Decline after Age 40 Years[J]. Plos One,2014,9(10):e109346.
[8]Lunenfeld B, Saad F, Hoesl C E. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males:scientific background and rationale[J]. Aging Male,2005,8(2):59-74.
[9]卿兴荣,王玲玲,王国洪,等.南京城区中老年男性生殖激素及相关指标分析[J].中华男科学杂志,2014,20(4):347-353.
[10]陈坚,潘钦石,王瑜敏,等.男性睾酮水平及中老年男性雄激素部分缺乏综合征患病率分析[J].中国全科医学,2016,19(30):3685-3690.
[11]Berg W T, Sheynkin Y, Schulsinger D. MP01-01 STENT EARLY ENCRUSTATION(SEE)STUDY:FACTORS ASSOCIATED W ITH ACUTE CALCIFICATIONS[J]. Journal of Urology,2017,197(4):e1.
[12]李浩,米庆辉,高用军,等.前列舒通胶囊联合坦索罗辛对良性前列腺增生患者血清睾酮、雌二醇水平的影响及其临床疗效研究[J].中国生化药物杂志,2015,35(3):89-91.
[13]Arai S, Shibata Y, Miyashiro Y, et al. AGE-RELATED CHANGES OF ADRENAL ANDROGEN ANDESTROGEN LEVELSINTHE PROSTATIC TISSUE WITH BENIGN PROSTATIC HYPERPLASIA[J].Journal of Urology,2009,181(4):504-504.
[14]La V S, Condorelli R A, Russo G I, et al. Endocrine control of benign prostatic hyperplasia[J]. Andrology,2016,4(3):404-411.
[15]郑入文,胡慧.60例良性前列腺增生患者雌、雄激素水平与症状指标的相关性分析[J].中华中医药杂志,2018(6).
[16]杜传策,宋乐明,胡敏,等.前列腺体积与血清雌二醇和睾酮浓度及其比例关系的研究[J].中国全科医学,2011,14(2):159-160.
[17]Lu M L, Schneider M C, Zheng Y, et al. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation[J]. Journal of Biological Chemistry, 2001, 276(16):13442-13451.
[18]Lai K P, Huang C K, Fang L Y, et al. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia(BPH)[J]. Molecular Endocrinology, 2013, 27(10):1617-1631.
[19]Wang X, Lin W J, Izumi K, et al. Increased infiltrated macrophages in benign prostatic hyperplasia(BPH):role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation[J]. Journal of Biological Chemistry, 2012, 287(22):18376-85.
[20]Lee KL, Peehl DM.Molecular and cellular pathogenesis of benign prostatic hyperplasia[J]. Urol,2004,172(5):1784-1791.
[21]Gallagher E J, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome[J]. Mount Sinai JournalofMedicineAJournalofTranslational&Personalized Medicine,2010,77(5):511-523.
[22]Goncharov N P, Katsya G V, Chagina N A, et al. Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone[J]. Aging Male, 2008, 11(3):118-122.
[23]Moulana M, Lima R, Reckelhoff J F. Metabolic syndrome, androgens, and hypertension[J]. Current Hypertension Reports, 2011, 13(2):158-162.
[24]Jones T H. Testosterone deficiency:a risk factor for cardiovascular disease?[J]. Trends in Endocrinology&Metabolism, 2010, 21(8):496-503.
[25]Korpachevazinych O V, Savyts'Ka V V. Androgen metabolism in men with diabetes mellitus type II depending on sensitivity to insulin and androgens[J].Likarska Sprava, 2008(3-4):3-10.
[26]Alonso-Magdalena P, Br?ssner C, Relner A, et al. A Role for EpithelialMesenchymal Transition in the Etiology of Benign Prostatic Hyperplasia[J].Proceedings of the National Academy of Sciences of the United States of America, 2009,106(8):2859-2863.
[27]Yu S, Zhang C, Lin C C, et al. Altered Prostate Epithelial Development and IGF-1 Signal in Mice Lacking the Androgen Receptor in Smooth Muscle Cells[J]. Prostate, 2011, 71(5):517-524.
[28]Lai K P, Yamashita S, Vitkus S, et al. Suppressed prostate epithelial developmentwithimpairedbranchingmorphogenesisinmice lackingstromalfibromuscularandrogenreceptor[J].Molecular Endocrinology,2012,26(1):52-66.
[29]熊宇,黄涛,吴奎,等.IGF-1及IGF-1R在SD大鼠前列腺组织中的表达[J].安徽医科大学学报,2015,50(9):1247-1251.
[30]Mclaren I D, Jerde T J, Bushman W. Role of interleukins, IGF and stem cells in BPH[J]. Differentiation,2011,82(4-5):237-243.
[31]Sampson N, Zenzmaier C, Heitz M, et al. Stromal insulin-like growth factor binding protein 3(IGFBP3)is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation[J].Endocrinology, 2013, 154(8):2586-2599.
[32]Park Y W, Kim S B, Kwon H, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome[J]. Urology, 2013, 82(3):674-679.
[33]Lee R K, Chung D, Chughtai B, et al. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms[J].Bju International, 2012, 110(4):540-545.
[34]Hammarsten J, H?gstedt B, Holthuis N, et al. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia[J].Prostate Cancer Prostatic Dis, 1998, 1(1):157-162.
[35]Roberts C K, Hevener A L, James B R. Metabolic syndrome and insulin resistance:underlying causes and modification by exercise training[J].Comprehensive Physiology, 2013, 3(1):1-58.
[36]Vikram A, Jena G B, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats:linking hyperinsulinemia with benign prostate hyperplasia[J]. Prostate,2010,70(1):79-89.
[37]申旭波,熊世敏,刘方苇,等.中老年男性血清性激素水平与代谢综合征的相关性[J].中华疾病控制杂志,2018(3).
[38]Tajar A, Forti G, O'Neill T W, et al. Characteristics of Secondary, Primary,and Compensated Hypogonadism in Aging Men:Evidence from the European Male Ageing Study[J]. Journal of Clinical Endocrinology&Metab olism,2010,95(4):1810-1818.
[2]Asiedu B, Anang Y, Nyarko A, et al. The role of sex steroid hormones in benign prostatic hyperplasia[J]. Aging Male, 2017, 20(1):17-22.
[3]Rogol A D. Androgens and puberty[J]. Molecular&Cellular Endocrinology,2002, 198(1):25-29.
[4]Gao W, Bohl C E, Dalton J T. Chemistry and structural biology of androgen receptor[J]. Chemical Reviews, 2005, 105(9):3352-70.
[5]Lamberts S W, Vandenbeld A W, Vanderlely A J. The endocrinology of aging[J]. Science,1997,278(5337):419.
[6]Kaplan S A, O'Neill E, Lowe R, et al. Prevalence of low testosterone in aging men with benign prostatic hyperplasia:data from the Proscar Long-term Efficacy and Safety Study(PLESS)[J]. Aging Male, 2013, 16(2):48-51.
[7]Kelsey T W, Li L Q, Mitchell R T, et al. A Validated Age-Related Normative Model for Male Total Testosterone Shows Increasing Variance but No Decline after Age 40 Years[J]. Plos One,2014,9(10):e109346.
[8]Lunenfeld B, Saad F, Hoesl C E. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males:scientific background and rationale[J]. Aging Male,2005,8(2):59-74.
[9]卿兴荣,王玲玲,王国洪,等.南京城区中老年男性生殖激素及相关指标分析[J].中华男科学杂志,2014,20(4):347-353.
[10]陈坚,潘钦石,王瑜敏,等.男性睾酮水平及中老年男性雄激素部分缺乏综合征患病率分析[J].中国全科医学,2016,19(30):3685-3690.
[11]Berg W T, Sheynkin Y, Schulsinger D. MP01-01 STENT EARLY ENCRUSTATION(SEE)STUDY:FACTORS ASSOCIATED W ITH ACUTE CALCIFICATIONS[J]. Journal of Urology,2017,197(4):e1.
[12]李浩,米庆辉,高用军,等.前列舒通胶囊联合坦索罗辛对良性前列腺增生患者血清睾酮、雌二醇水平的影响及其临床疗效研究[J].中国生化药物杂志,2015,35(3):89-91.
[13]Arai S, Shibata Y, Miyashiro Y, et al. AGE-RELATED CHANGES OF ADRENAL ANDROGEN ANDESTROGEN LEVELSINTHE PROSTATIC TISSUE WITH BENIGN PROSTATIC HYPERPLASIA[J].Journal of Urology,2009,181(4):504-504.
[14]La V S, Condorelli R A, Russo G I, et al. Endocrine control of benign prostatic hyperplasia[J]. Andrology,2016,4(3):404-411.
[15]郑入文,胡慧.60例良性前列腺增生患者雌、雄激素水平与症状指标的相关性分析[J].中华中医药杂志,2018(6).
[16]杜传策,宋乐明,胡敏,等.前列腺体积与血清雌二醇和睾酮浓度及其比例关系的研究[J].中国全科医学,2011,14(2):159-160.
[17]Lu M L, Schneider M C, Zheng Y, et al. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation[J]. Journal of Biological Chemistry, 2001, 276(16):13442-13451.
[18]Lai K P, Huang C K, Fang L Y, et al. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia(BPH)[J]. Molecular Endocrinology, 2013, 27(10):1617-1631.
[19]Wang X, Lin W J, Izumi K, et al. Increased infiltrated macrophages in benign prostatic hyperplasia(BPH):role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation[J]. Journal of Biological Chemistry, 2012, 287(22):18376-85.
[20]Lee KL, Peehl DM.Molecular and cellular pathogenesis of benign prostatic hyperplasia[J]. Urol,2004,172(5):1784-1791.
[21]Gallagher E J, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome[J]. Mount Sinai JournalofMedicineAJournalofTranslational&Personalized Medicine,2010,77(5):511-523.
[22]Goncharov N P, Katsya G V, Chagina N A, et al. Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone[J]. Aging Male, 2008, 11(3):118-122.
[23]Moulana M, Lima R, Reckelhoff J F. Metabolic syndrome, androgens, and hypertension[J]. Current Hypertension Reports, 2011, 13(2):158-162.
[24]Jones T H. Testosterone deficiency:a risk factor for cardiovascular disease?[J]. Trends in Endocrinology&Metabolism, 2010, 21(8):496-503.
[25]Korpachevazinych O V, Savyts'Ka V V. Androgen metabolism in men with diabetes mellitus type II depending on sensitivity to insulin and androgens[J].Likarska Sprava, 2008(3-4):3-10.
[26]Alonso-Magdalena P, Br?ssner C, Relner A, et al. A Role for EpithelialMesenchymal Transition in the Etiology of Benign Prostatic Hyperplasia[J].Proceedings of the National Academy of Sciences of the United States of America, 2009,106(8):2859-2863.
[27]Yu S, Zhang C, Lin C C, et al. Altered Prostate Epithelial Development and IGF-1 Signal in Mice Lacking the Androgen Receptor in Smooth Muscle Cells[J]. Prostate, 2011, 71(5):517-524.
[28]Lai K P, Yamashita S, Vitkus S, et al. Suppressed prostate epithelial developmentwithimpairedbranchingmorphogenesisinmice lackingstromalfibromuscularandrogenreceptor[J].Molecular Endocrinology,2012,26(1):52-66.
[29]熊宇,黄涛,吴奎,等.IGF-1及IGF-1R在SD大鼠前列腺组织中的表达[J].安徽医科大学学报,2015,50(9):1247-1251.
[30]Mclaren I D, Jerde T J, Bushman W. Role of interleukins, IGF and stem cells in BPH[J]. Differentiation,2011,82(4-5):237-243.
[31]Sampson N, Zenzmaier C, Heitz M, et al. Stromal insulin-like growth factor binding protein 3(IGFBP3)is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation[J].Endocrinology, 2013, 154(8):2586-2599.
[32]Park Y W, Kim S B, Kwon H, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome[J]. Urology, 2013, 82(3):674-679.
[33]Lee R K, Chung D, Chughtai B, et al. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms[J].Bju International, 2012, 110(4):540-545.
[34]Hammarsten J, H?gstedt B, Holthuis N, et al. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia[J].Prostate Cancer Prostatic Dis, 1998, 1(1):157-162.
[35]Roberts C K, Hevener A L, James B R. Metabolic syndrome and insulin resistance:underlying causes and modification by exercise training[J].Comprehensive Physiology, 2013, 3(1):1-58.
[36]Vikram A, Jena G B, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats:linking hyperinsulinemia with benign prostate hyperplasia[J]. Prostate,2010,70(1):79-89.
[37]申旭波,熊世敏,刘方苇,等.中老年男性血清性激素水平与代谢综合征的相关性[J].中华疾病控制杂志,2018(3).
[38]Tajar A, Forti G, O'Neill T W, et al. Characteristics of Secondary, Primary,and Compensated Hypogonadism in Aging Men:Evidence from the European Male Ageing Study[J]. Journal of Clinical Endocrinology&Metab olism,2010,95(4):1810-1818.